## **Patent Claims**

- Medical-technology product with a layer of a hybrid complex material composed of a branched amphiphilic macromolecule and of a metal nanoparticle, the layer having been provided at least on the surface and on the surface at least on a portion of the surface.
- 2. Medical-technology product according to Claim 1, wherein each metal nanoparticle has been surrounded in the manner of a capsule by at least one branched amphiphilic macromolecule.
- 3. Medical-technology product according to Claim 1, wherein the amphiphilic macromolecule is an amphiphilic polyalkyleneimine.
- Medical-technology product according to Claim 1, wherein the amphiphilic macromolecule is an amphiphilic polyalkyleneimine with a degree of branching of 20% to 90%.
- 5. Medical-technology product according to Claim 1, wherein the amphiphilic macromolecule is an amphiphilic polyalkyleneimine that has alkyl-substituted secondary or tertiary amino groups.
- Medical-technology product according to Claim 1, wherein the amphiphilic
  macromolecule is a branched amphiphilic polyalkyleneimine which has amide groups, where the N atoms of the amide groups derive from the polyalkyleneimine.
- 7. Medical-technology product according to Claim 1, wherein the amphiphilic macromolecule is a branched amphiphilic polyalkyleneimine which has amide groups directed away from the metal nanoparticle and where the N atoms of the amide groups derive from the polyalkyleneimine.
- 8. Medical-technology product according to Claim 6, wherein the amide groups have an aliphatic radical of a fatty acid having from 6 to 22 carbon atoms.

- Medical-technology product according to Claim 6, wherein the amide groups have an aliphatic radical of a fatty acid, oriented towards the outside, having from 6 to 22 carbon atoms.
- Medical-technology product according to Claim 1, wherein the molecular weight of the macromolecule is from 800 to 20 000.
- 11. Medical-technology product according to Claim 1, wherein the metal nanoparticle is a silver nanoparticle or a copper nanoparticle.
- 12. Medical-technology product according to Claim 3, wherein the metal nanoparticle is a silver nanoparticle with a ratio of silver atoms to nitrogen atoms in direct contact with the silver atoms is from 1:2 to 1:10.
- 13. Medical-technology product according to Claim 1, wherein the diameter of the hybrid complex is from 0.5 to 10 nm.
- 14. Medical-technology product according to Claim 1, wherein the diameter of the hybrid complex is about 2 nm.
- 15. Medical-technology product according to Claim 1, wherein the product is a temporary or long-lasting implant for the body of a human or of an animal.
- 16. Medical-technology product according to Claim 1, wherein the product is a medical instrument.
- 17. Medical-technology product according to Claim 1, wherein the material of the product is metal.
- 18. Medical-technology product according to Claim 1, wherein the material of the product is non-resorbable or at least to some extent resorbable polymers.

- 19. Medical-technology product according to Claim 1, wherein the material of the product is ceramic.
- 20. Medical-technology product according to Claim 1, wherein the product is sterilizable.
- 21. Medical-technology product with a biocide in the form of a hybrid complex material composed of a branched amphiphilic macromolecule and of a metal nanoparticle.
- 22. Medical-technology product according to Claim 21, wherein the biocide has been applied to at least a portion of the surface of the medical-technology product.
- 23. Medical-technology product according to Claim 21, wherein the biocide has been incorporated into the interior of the medical-technology product.
- 24. Medical-technology product according to Claim 21, wherein the biocide has been applied to at least one portion of the surface and into the interior of the medical-technology product.
- 25. Medical-technology product according to Claim 21, wherein each metal nanoparticle has been surrounded in the manner of a capsule by at least one branched amphiphilic macromolecule.
- 26. Process for producing a hybrid complex material composed of a branched amphiphilic macromolecule and of a metal nanoparticle by dissolving a metal compound in a solution of an amphiphilic polyalkyleneimine with complexing, followed by reduction of the metal compound.
- 27. Process according to Claim 26, wherein each metal nanoparticle has been surrounded in the manner of a capsule by at least one branched amphiphilic macromolecule.

- 28. Process according to Claim 26, wherein the metal compound is a silver salt.
- Process for producing medical-technology products according to Claim 1,
   wherein the hybrid complex material is applied from outside to the product.
- 30. Process for producing medical-technology products according to Claim 1, wherein the hybrid complex material is applied from outside to the product in the form of a solution.
- 31. Process for producing medical-technology products according to Claim 1, wherein the hybrid complex material is added to the polymer material of the product during its production.
- 32. Process according to Claim 31, wherein the hybrid complex material is mixed and moulded with the material used to produce the product.
- 33. Process according to Claim 31, wherein the hybrid complex material is mixed and spun with the material used to produce the product.